A defined FDA-approved use
The FDA-approved DUOLITH SD1 indication includes heel pain due to chronic proximal plantar fasciitis in adults who have not improved after at least six months of alternative conservative therapies. Other diagnoses or protocols may be outside that approved indication.
Other areas of clinical interest
Researchers and clinicians have evaluated shockwave techniques for selected tendinopathies and musculoskeletal pain. Evidence for particular problems—including erectile dysfunction—is not interchangeable with the plantar-fasciitis FDA approval. Any off-label discussion requires individualized assessment.
Before treatment
A clinician should screen for bleeding disorders, anticoagulant use, local infection, prosthetic devices, malignancy near the site and other labeling-based precautions. Temporary discomfort and bruising can occur.